Discontinued — last reported Q2 '23
Merck & Co. Available-for-Sale Debt and Equity Securities (FV-NI) decreased by 11.7% to $1.49B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 2.5%, from $1.46B to $1.49B. Over 5 years (FY 2020 to FY 2025), Available-for-Sale Debt and Equity Securities (FV-NI) shows a downward trend with a -4.5% CAGR.
An increase indicates a larger portfolio of market-sensitive assets, which may lead to higher earnings volatility.
This metric captures the fair value of debt and equity securities where fluctuations in market price are recognized dire...
Standard for firms that have adopted specific accounting standards for fair value reporting of investment portfolios.
afs_debt_and_equity_securities_fv_ni| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.67B | $2.00B | $1.73B | $1.85B | $1.94B | $1.41B | $1.85B | $2.35B | $2.34B | $1.99B | $1.10B | $1.03B | $1.15B | $1.07B | $1.46B | $1.72B | $1.89B | $1.69B | $1.49B |
| QoQ Change | — | +20.2% | -13.5% | +6.8% | +4.9% | -27.4% | +31.4% | +26.6% | -0.2% | -14.9% | -44.8% | -6.9% | +12.5% | -7.6% | +36.7% | +18.3% | +9.6% | -10.4% | -11.7% |
| YoY Change | — | — | — | — | +16.5% | -29.6% | +6.9% | +26.7% | +20.5% | +41.3% | -40.6% | -56.3% | -50.7% | -46.6% | +32.2% | +68.1% | +63.7% | +58.8% | +2.5% |
We use cookies for analytics. See our Privacy and Cookie Policy.